Franco-Nevada Corporation
FNVFranco-Nevada Corporation is coiled. The quarters are improving, yet the P/E sits at the 4th percentile of its own 4-year range — the business is moving before the market.
The sharpest disagreement: annual EPS moved +100.7% against a +35.4% price move — the market has not yet caught up with the delivery.
The price is building a base (10 weeks in) while the P/E sits at the 4th percentile of its own 4-year range. Underneath, the last four quarters read improving — profit +123.8% year on year, and 141% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Franco-Nevada Corporation trades at $219, building a base and 10 weeks into that stage. That is −3.2% against its own 200-day average. It sits at 40% of a 52-week range of $177 to $281. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (16 weeks and counting).
Today the stock is building a base — week 10 of stage 1. At $219 it trades −3.2% versus its 200-day average and sits at 40% of its 52-week range ($177–$281).
Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +176% while the S&P 500 moved +263% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (16 weeks and counting; last ahead the week of 2026-04-17) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Franco-Nevada Corporation trades at 30.0× P/E, near the bottom of its own range — cheaper only 4% of the time. Its long-run median P/E is 39.2×, measured across 4.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 30.0× is near the bottom of its own range — cheaper only 4% of the time, against a long-run median of 39.2× measured over 4.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
One caveat before moving on: margins are the best this company has ever printed — cheap against its own history on record margins is not the same thing as cheap. If profitability mean-reverts, today's multiple is higher than it looks.
Why the multiple sits where it does: over the past year annual EPS moved +100.7% against a +35.4% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 3y, of the +16.1%/yr price move, ~+27.2%/yr came from earnings growth and ~−11.1 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Franco-Nevada Corporation reads as improving on its fundamental arc. Improving — profit growth bottomed 6 quarters ago at −187.5% and has held its recovery at +122.6%, ROCE lifting at 22.1%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +64.0% | +11.3% | — | — |
| Profit | +101.8% | +16.6% | — | — |
| EPS | +100.7% | +16.4% | — | — |
| Stock price | +35.4% | +16.1% | +6.9% | +11.0% |
4-Factor Sector Score
65.4/100 — rank 1 of 28 in Gold · 81% evidence confidence
Franco-Nevada Corporation scores 65.4 out of 100 against the 28 companies it is compared with in Gold, ranking 1. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 25.2 + 14 + 10.2 + 16 = 65.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Franco-Nevada Corporation reported $0.7 B of revenue in the Mar 26 quarter, +75.7% year on year. That is the 6th straight quarter of year-on-year growth. Over 4 years it has compounded at 8.8% a year. The last full year, FY25, came in at $1.8 B. The last four reported quarters add to $2.1 B.
FY25 revenue came in at $1.8 B (+64.0% on the year), capping 4 years at 8.8% compound. The latest quarter (Mar 26) printed $0.7 B, +75.7% year on year — the 6th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +70.1% growth against the decade's 8.8% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +71.5% over the last 4 quarters against +32.6%/yr over the last 8 — accelerating.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Franco-Nevada Corporation's operating margin is 89.2% in the Mar 26 quarter, +21.6 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged −35.2% to 74.2%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 89.2%, +21.6 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −35.2%–74.2%, and FY25's 74.2% is the top of that band — a record year.
Why the margin moved: operating margin went +21.6 pp year on year while gross margin went +11.2 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Franco-Nevada Corporation earned $0.5 B of net profit in the Mar 26 quarter, +123.8% year on year. It is the 5th consecutive quarter of growth. Full-year FY25 profit was $1.1 B. The 4-year compound rate is 11.0%. That is 72.3% of the quarter's revenue. The same quarter a year earlier earned $0.2 B.
Mar 26 profit was $0.5 B, +123.8% year on year — the 5th consecutive quarter of growth. On the full year, FY25 printed $1.1 B (+101.8%), and the 4-year compound rate is 11.0%.
Why profit moved: revenue contributed +75.7% and the margin +21.6 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +133.8% vs revenue +70.1%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 141% of Franco-Nevada Corporation's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $1.5 B of operating cash against $1.1 B of profit. After $0.0 B of capital spending, $1.5 B was left as free cash.
FY25: operating cash of $1.5 B against reported profit of $1.1 B, leaving free cash of $1.5 B after $0.0 B of capital spending. Across the last 3 fiscal years the conversion rate is 141% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Franco-Nevada Corporation does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Franco-Nevada Corporation earns a ROE of 15% in FY25. That is up from a trough of −8% in FY23. Return on invested capital clears the cost of that capital by +8.4 percentage points, so growth here adds value rather than only size. The wiring behind it is 61.0% net margin on 0.22× asset turns.
FY25 ROE is 15%, recovered from a FY23 trough of −8% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 61.0% net margin × 0.22× asset turns × 1.08× balance-sheet leverage ≈ 14.5% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 17.6% − 9.2% = a +8.4 pp spread. The 9.2% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
Franco-Nevada Corporation paid $1.58 per share over the last four reported quarters, up 15.8% on a year ago. The most recent declaration was $0.44 for Mar 26. Against the current price of $219 that is a trailing yield of 0.72%, measured on dividends already paid rather than on a forecast.
Franco-Nevada Corporation paid $1.58 per share across the last four reported quarters, most recently $0.44 for Mar 26. That is up 15.8% against the same quarter a year earlier. Against the current price of $219 the trailing twelve months work out to 0.72% — trailing dividends measured against today's price, not a forward estimate.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Franco-Nevada Corporation carries total debt of $0.0 B against shareholder equity of $8.1 B as of Mar 26, a debt-to-equity of 0.00 — effectively unlevered. On the annual view that ratio went from 0.00 in FY21 to 0.00 in FY25. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of $0.0 B against shareholder equity of $8.1 B — a debt-to-equity of 0.00. On the annual view, debt-to-equity went from 0.00 (FY21) to 0.00 (FY25). The returns on this page are earned, not borrowed.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
1.7% of Franco-Nevada Corporation's tradable float is currently sold short — the crowd is not positioned against this stock. At typical trading volumes those positions would take about 3.8 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 1.7% of the float is sold short, and at typical trading volumes it would take about 3.8 days to buy those positions back. The crowd is not positioned against this stock. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Franco-Nevada Corporation: the Z-score reads 34.53. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 34.53 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 34.53.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Franco-Nevada Corporationthis pageFNV | 65.4/100Favorable setup81% evidence | ASLEEP | 25.2/35 Revenue 71.8% · PAT 100% · OPM change 20 pp 83% evidence | 14.0/25 ROCE 7.6% · OPM 88.8% 76% evidence | 10.2/20 P/E 34.8× · PEG 1.31 65% evidence | 16.0/20 RS sector 4.2% · RS bench -11% · 1Y 27.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 25.2 + 14 + 10.2 + 16 = 65.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Wheaton Precious Metals Corp.WPM | 62.7/100Mixed-positive evidence81% evidence | BASING | 25.3/35 Revenue 88.3% · PAT 100% · OPM change 13.1 pp 83% evidence | 14.9/25 ROCE 7.9% · OPM 74.9% 76% evidence | 9.6/20 P/E 33.1× · PEG 1.36 65% evidence | 12.9/20 RS sector 1.6% · RS bench -13.8% · 1Y 14.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 25.3 + 14.9 + 9.6 + 12.9 = 62.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Barrick Mining CorporationB | 62.2/100Mixed-positive evidence71% evidence | ASLEEP | 24.6/35 Revenue 43.1% · PAT 100% · OPM change 26.8 pp 83% evidence | 13.0/25 ROCE 6.9% · OPM 62.6% 76% evidence | 10.2/20 P/E 11.3× · PEG — 15% evidence | 14.4/20 RS sector 3.7% · RS bench -12.3% · 1Y 63.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 24.6 + 13 + 10.2 + 14.4 = 62.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Fortuna Mining Corp.FSM | 61.6/100Mixed-positive evidence71% evidence | ASLEEP | 24.5/35 Revenue 50.1% · PAT 100% · OPM change 23.9 pp 83% evidence | 13.0/25 ROCE 8.8% · OPM 52.6% 76% evidence | 11.0/20 P/E 9.4× · PEG — 15% evidence | 13.1/20 RS sector 1.6% · RS bench -13.7% · 1Y 37.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 24.5 + 13 + 11 + 13.1 = 61.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5IAMGOLD CorporationIAG | 60.2/100Mixed-positive evidence81% evidence | ASLEEP | 24.4/35 Revenue 92.3% · PAT 47.3% · OPM change 29.2 pp 83% evidence | 12.7/25 ROCE 10.5% · OPM 52.9% 76% evidence | 15.7/20 P/E 10.9× · PEG 0.46 65% evidence | 7.4/20 RS sector 0.7% · RS bench -15.9% · 1Y 97.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 24.4 + 12.7 + 15.7 + 7.4 = 60.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Aura Minerals Inc.AUGO | 59.7/100Mixed-positive evidence74% evidence | ASLEEP | 22.1/35 Revenue 83.2% · PAT — · OPM change 12.5 pp 62% evidence | 17.5/25 ROCE 20.8% · OPM 53.7% 76% evidence | 8.2/20 P/E 75.6× · PEG 1.56 65% evidence | 11.9/20 RS sector 10.6% · RS bench -8.9% · 1Y 120.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 17.5 + 8.2 + 11.9 = 59.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7OceanaGold CorporationOGC | 59.1/100Mixed-positive evidence71% evidence | ASLEEP | 19.0/35 Revenue 62.5% · PAT 35.8% · OPM change -8.1 pp 83% evidence | 21.9/25 ROCE 42.7% · OPM 152.9% 76% evidence | 11.2/20 P/E 9× · PEG — 15% evidence | 7.0/20 RS sector -3% · RS bench -18.9% · 1Y 52.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 21.9 + 11.2 + 7 = 59.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Royal Gold, Inc.RGLD | 57.7/100Thin evidence · provisional53% evidence | ASLEEP | 19.3/35 Revenue 70.7% · PAT 60.4% · OPM change — 45% evidence | 14.3/25 ROCE — · OPM — 15% evidence | 13.3/20 P/E 30.3× · PEG 0.78 65% evidence | 10.8/20 RS sector -1.2% · RS bench -16.5% · 1Y 21.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.3 + 14.3 + 13.3 + 10.8 = 57.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Centerra Gold Inc.CGAU | 55.1/100Thin evidence · provisional58% evidence | ASLEEP | 16.7/35 Revenue — · PAT — · OPM change 8.1 pp 45% evidence | 7.3/25 ROCE 5.2% · OPM 22.4% 76% evidence | 11.4/20 P/E 4.9× · PEG — 15% evidence | 19.7/20 RS sector 30.9% · RS bench 9.6% · 1Y 158.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.7 + 7.3 + 11.4 + 19.7 = 55.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10B2Gold Corp.BTG | 54.9/100Mixed-positive evidence74% evidence | BASING | 21.8/35 Revenue 86.9% · PAT — · OPM change 9.8 pp 62% evidence | 14.0/25 ROCE 12.4% · OPM 49% 76% evidence | 13.0/20 P/E 12.6× · PEG 0.97 65% evidence | 6.1/20 RS sector -11% · RS bench -23.8% · 1Y 8.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21.8 + 14 + 13 + 6.1 = 54.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11AngloGold Ashanti plcAU | 53.1/100Thin evidence · provisional58% evidence | ASLEEP | 18.4/35 Revenue — · PAT — · OPM change 17.9 pp 45% evidence | 15.2/25 ROCE 11.8% · OPM 55.9% 76% evidence | 10.8/20 P/E 10.8× · PEG — 15% evidence | 8.7/20 RS sector 1.4% · RS bench -14.7% · 1Y 41.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 15.2 + 10.8 + 8.7 = 53.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Newmont CorporationNEM | 52.8/100Thin evidence · provisional58% evidence | ASLEEP | 16.5/35 Revenue — · PAT — · OPM change 16.2 pp 45% evidence | 11.5/25 ROCE 6% · OPM 61.1% 76% evidence | 10.1/20 P/E 11.8× · PEG — 15% evidence | 14.7/20 RS sector 4.4% · RS bench -11.7% · 1Y 41.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 11.5 + 10.1 + 14.7 = 52.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Aris Mining CorporationARIS | 51.6/100Thin evidence · provisional58% evidence | ASLEEP | 18.4/35 Revenue — · PAT — · OPM change 16.5 pp 45% evidence | 11.2/25 ROCE 7.7% · OPM 54.8% 76% evidence | 10.9/20 P/E 10.8× · PEG — 15% evidence | 11.1/20 RS sector 6.4% · RS bench -11.7% · 1Y 97.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 11.2 + 10.9 + 11.1 = 51.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14SSR Mining Inc.SSRM | 50.1/100Mixed-positive evidence81% evidence | ASLEEP | 23.1/35 Revenue 75.7% · PAT 100% · OPM change 17.9 pp 83% evidence | 8.1/25 ROCE 4.7% · OPM 51.6% 76% evidence | 6.7/20 P/E 28× · PEG 2.09 65% evidence | 12.2/20 RS sector 9.8% · RS bench -6.5% · 1Y 75%1 of 12 weeks ahead 100% evidence |
| Exact sum: 23.1 + 8.1 + 6.7 + 12.2 = 50.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15OR Royalties Inc.OR | 49.8/100Mixed-negative evidence71% evidence | BASING | 21.7/35 Revenue 61.7% · PAT 100% · OPM change 15.3 pp 83% evidence | 11.8/25 ROCE 5.9% · OPM 85.4% 76% evidence | 9.1/20 P/E 28.4× · PEG — 15% evidence | 7.2/20 RS sector -10.8% · RS bench -23.8% · 1Y 1.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21.7 + 11.8 + 9.1 + 7.2 = 49.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Eldorado Gold CorporationEGO | 49.8/100Thin evidence · provisional58% evidence | ASLEEP | 16.8/35 Revenue — · PAT — · OPM change 19.2 pp 45% evidence | 7.8/25 ROCE 2.8% · OPM 51.4% 76% evidence | 10.5/20 P/E 11.1× · PEG — 15% evidence | 14.7/20 RS sector 3.4% · RS bench -12.7% · 1Y 40.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.8 + 7.8 + 10.5 + 14.7 = 49.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Kinross Gold CorporationKGC | 49.5/100Thin evidence · provisional58% evidence | ASLEEP | 19.0/35 Revenue — · PAT — · OPM change 17.5 pp 45% evidence | 13.9/25 ROCE 10.5% · OPM 55.6% 76% evidence | 11.3/20 P/E 9× · PEG — 15% evidence | 5.3/20 RS sector -9% · RS bench -23.1% · 1Y 24.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 13.9 + 11.3 + 5.3 = 49.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18Orla Mining Ltd.ORLA | 49.3/100Mixed-negative evidence74% evidence | 22.8/35 Revenue 100% · PAT 100% · OPM change 1.8 pp 62% evidence | 19.7/25 ROCE 34.3% · OPM 136.8% 76% evidence | 4.5/20 P/E 22.3× · PEG 2.92 65% evidence | 2.3/20 RS sector -19% · RS bench -33.1% · 1Y -0.8%0 of 11 weeks ahead 100% evidence | |
| Exact sum: 22.8 + 19.7 + 4.5 + 2.3 = 49.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -19% and the one-year return is -0.8%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 19Pan American Silver Corp.PAAS | 48.3/100Mixed-negative evidence71% evidence | ASLEEP | 21.0/35 Revenue 33.8% · PAT 100% · OPM change 18.5 pp 83% evidence | 9.5/25 ROCE 7% · OPM 48.1% 76% evidence | 9.5/20 P/E 17.6× · PEG — 15% evidence | 8.3/20 RS sector 0.5% · RS bench -15.6% · 1Y 40.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21 + 9.5 + 9.5 + 8.3 = 48.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Coeur Mining, Inc.CDE | 47.0/100Mixed-negative evidence71% evidence | ASLEEP | 22.9/35 Revenue 100% · PAT 100% · OPM change 23.5 pp 83% evidence | 6.1/25 ROCE 3.8% · OPM 40.8% 76% evidence | 9.8/20 P/E 15.5× · PEG — 15% evidence | 8.2/20 RS sector -4.9% · RS bench -19.6% · 1Y 39.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 22.9 + 6.1 + 9.8 + 8.2 = 47 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Agnico Eagle Mines LimitedAEM | 45.8/100Thin evidence · provisional58% evidence | BASING | 17.1/35 Revenue — · PAT — · OPM change 12.7 pp 45% evidence | 11.7/25 ROCE 5.7% · OPM 62.8% 76% evidence | 9.9/20 P/E 13.3× · PEG — 15% evidence | 7.1/20 RS sector -9.8% · RS bench -23.6% · 1Y 11.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 11.7 + 9.9 + 7.1 = 45.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Alamos Gold Inc.AGI | 45.6/100Thin evidence · provisional58% evidence | BASING | 20.6/35 Revenue — · PAT — · OPM change 29.4 pp 45% evidence | 12.5/25 ROCE 6.4% · OPM 57.8% 76% evidence | 10.6/20 P/E 11× · PEG — 15% evidence | 1.9/20 RS sector -17.9% · RS bench -30.8% · 1Y 9.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 20.6 + 12.5 + 10.6 + 1.9 = 45.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Equinox Gold Corp.EQX | 39.5/100Thin evidence · provisional53% evidence | ASLEEP | 21.0/35 Revenue — · PAT 98.7% · OPM change 48.8 pp 32% evidence | 7.8/25 ROCE 5.3% · OPM 45.3% 76% evidence | 9.4/20 P/E 18.3× · PEG — 15% evidence | 1.3/20 RS sector -18.2% · RS bench -31.3% · 1Y 48.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21 + 7.8 + 9.4 + 1.3 = 39.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24Hycroft Mining Holding CorporationHYMC | 38.3/100Mixed-negative evidence60% evidence | ASLEEP | 13.1/35 Revenue — · PAT — · OPM change 16.9 pp 52% evidence | 3.0/25 ROCE -10.1% · OPM -177.5% 76% evidence | 11.5/20 P/E 3× · PEG — 15% evidence | 10.7/20 RS sector 10.2% · RS bench -13.3% · 1Y 546.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.1 + 3 + 11.5 + 10.7 = 38.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Allied Gold CorporationAAUC | 28.2/100Adverse evidence64% evidence | ASLEEP | 9.8/35 Revenue 53% · PAT — · OPM change -9.6 pp 62% evidence | 7.1/25 ROCE 5.9% · OPM 14.7% 76% evidence | 9.7/20 P/E 16.6× · PEG — 15% evidence | 1.6/20 RS sector -14% · RS bench -28.6% · 1Y 60.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 9.8 + 7.1 + 9.7 + 1.6 = 28.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Gold Fields LimitedGFI | 49.2/100Thin evidence · provisional38% evidence | BASING | 18.4/35 Revenue — · PAT — · OPM change — 9% evidence | 15.5/25 ROCE 12.8% · OPM — 46% evidence | 10.3/20 P/E 11.1× · PEG — 15% evidence | 5.0/20 RS sector -13.9% · RS bench -27.1% · 1Y 9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 15.5 + 10.3 + 5 = 49.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Seabridge Gold Inc.SA | 43.7/100Thin evidence · provisional50% evidence | ASLEEP | 14.0/35 Revenue — · PAT — · OPM change — 33% evidence | 5.7/25 ROCE -0.4% · OPM — 61% evidence | 8.5/20 P/E 187.5× · PEG — 15% evidence | 15.5/20 RS sector 6% · RS bench -10.6% · 1Y 66.5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 14 + 5.7 + 8.5 + 15.5 = 43.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28NovaGold Resources Inc.NG | 30.5/100Thin evidence · provisional47% evidence | BASING | 13.9/35 Revenue — · PAT — · OPM change — 33% evidence | 5.2/25 ROCE -5.6% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 1.4/20 RS sector -21.5% · RS bench -33.7% · 1Y 11.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.9 + 5.2 + 10 + 1.4 = 30.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Franco-Nevada Corporation's stock price today?
Franco-Nevada Corporation trades at $219, +35.4% over the past year. The company is valued at $41.0 B. The stock sits at 40% of its 52-week range of $177–$281, −3.2% versus its 200-day average. On the tape, the price is building a base, 10 weeks in. — as of 5 August 2026.
What were Franco-Nevada Corporation's latest quarterly results?
Franco-Nevada Corporation reported revenue of $0.7 B and net profit of $0.5 B for the Mar 26 quarter. Revenue rose 75.7% and profit rose 123.8% year on year. Earnings per share were $2.43. The operating margin was 89.2%, 21.6 pp higher than a year earlier. — as of 5 August 2026.
What is Franco-Nevada Corporation's revenue?
Franco-Nevada Corporation reported revenue of $0.7 B in the Mar 26 quarter, +75.7% year on year. For the full FY25 fiscal year, revenue was $1.8 B (+64.0%). Over the last 4 years revenue compounded at 8.8% a year. — as of 5 August 2026.
What is Franco-Nevada Corporation's profit?
Franco-Nevada Corporation earned $0.5 B of net profit in the Mar 26 quarter, +123.8% year on year — the 5th straight quarter of growth. Full-year FY25 profit was $1.1 B. The operating margin ran 89.2% in the latest quarter. — as of 5 August 2026.
What is Franco-Nevada Corporation's market cap?
Franco-Nevada Corporation's market capitalisation is $41.0 B at a stock price of $219. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
What is Franco-Nevada Corporation's P/E ratio?
Franco-Nevada Corporation trades at a P/E of 30.0×, at the 4th percentile of its own 4-year range, against a long-run median of 39.2×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.
Does Franco-Nevada Corporation pay a dividend?
Yes — Franco-Nevada Corporation declared $0.44 per share for Mar 26, and $1.58 per share across the last four reported quarters. The latest quarter is up 15.8% on the same quarter a year earlier. — as of 5 August 2026.
What is Franco-Nevada Corporation's dividend per share?
Franco-Nevada Corporation's most recently declared dividend is $0.44 per share for Mar 26, giving $1.58 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 5 August 2026.
What is Franco-Nevada Corporation's dividend yield?
Franco-Nevada Corporation's trailing dividend yield is 0.72%: $1.58 declared per share across the last four reported quarters, against a share price of $219. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 5 August 2026.
Is Franco-Nevada Corporation overvalued?
On its own history, Franco-Nevada Corporation looks cheap against its own history: its P/E of 30.0× has been cheaper only 4% of the time in 4 years (long-run median 39.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 5 August 2026.
Is Franco-Nevada Corporation growing?
Yes — Franco-Nevada Corporation is growing: latest-quarter revenue +75.7% year on year, profit +123.8%, and the margin +21.6 pp at 89.2%. The 4-year compound rates are 8.8% (revenue) and 11.0% (profit). The earnings engine currently reads: improving — as of 5 August 2026.
How is Franco-Nevada Corporation performing?
Franco-Nevada Corporation is building a base, 10 weeks in. Its latest quarter's revenue rose 75.7% and profit rose 123.8% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 16 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is Franco-Nevada Corporation in?
Improving — profit growth bottomed 6 quarters ago at −187.5% and has held its recovery at +122.6%, ROCE lifting at 22.1%. The read comes from the last 12 quarters of growth (revenue growth +71.5% latest, profit growth +122.6% latest, eps growth +121.9% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is Franco-Nevada Corporation in an uptrend?
No — the price is building a base (week 10 of stage 1), trading −3.2% versus its 200-day average and at 40% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is Franco-Nevada Corporation beating the market?
Not lately — on a trailing-13-week view Franco-Nevada Corporation is currently behind the S&P 500 (16 weeks and counting; last ahead the week of 2026-04-17), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +176% against the S&P 500's +263% — behind the index over the full window. — as of 5 August 2026.
Will Franco-Nevada Corporation's stock price go up?
This page publishes no price forecast for Franco-Nevada Corporation. What it measures instead: the stock price is $219, the price is building a base 10 weeks in. Its P/E of 30.0× sits at the 4th percentile of its own 4-year range. Direction is not something this site claims to know. — as of 5 August 2026.
Is the market betting against Franco-Nevada Corporation?
No — short interest is 1.7% of Franco-Nevada Corporation's tradable float, about 3.8 days to cover at typical volumes. That is a low reading: the crowd is not positioned against this stock. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
What is Franco-Nevada Corporation's capex?
Franco-Nevada Corporation spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 5 August 2026.
What is Franco-Nevada Corporation's cash flow?
Franco-Nevada Corporation generated $1.5 B of operating cash flow in FY25 and $1.5 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $1.1 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is Franco-Nevada Corporation's profit real cash?
Yes — over the last 3 fiscal years, 141% of Franco-Nevada Corporation's reported profit arrived as operating cash. In FY25, operating cash was $1.5 B against reported profit of $1.1 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is Franco-Nevada Corporation?
On the balance sheet, the Z-score reads 34.53 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.
Where is Franco-Nevada Corporation in its business cycle?
Franco-Nevada Corporation's FY25 operating margin was 74.2%, against a 5-year band of −35.2%–74.2%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 89.2%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Franco-Nevada Corporation story?
The sharpest disagreement: annual EPS moved +100.7% against a +35.4% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Franco-Nevada Corporation a stock worth studying right now?
This is not investment advice. The machine read: Franco-Nevada Corporation is coiled. The quarters are improving, yet the P/E sits at the 4th percentile of its own 4-year range — the business is moving before the market. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.